Michael Stanley - Mednax President - Pediatrix Division
| MD Stock | USD 9.03 0.22 2.50% |
President
Dr. Michael D. Stanley M.D. is no longer a President Clinical Services Division of the Company. effective December 31 2016. Dr. Stanley previously served as our President Pediatrix Division from February 2012 until April 2015 and prior thereto as our Regional President South Central Region for the Pediatrix Division from January 2002 until February 2012 and as our Vice President of Medical Operations South Central Region prior to that time. Dr. Stanley is board certified in pediatrics and neonatalperinatal medicine. since 2015.
| Age | 68 |
| Tenure | 9 years |
| Address | 1301 Concord Terrace, Sunrise, FL, United States, 33323 |
| Phone | 954 384 0175 |
| Web | https://www.pediatrix.com |
Mednax Management Efficiency
The company has Return on Asset (ROA) of 0.0432 % which means that for every $100 of assets, it generated a profit of $0.0432. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.0694) %, which implies that it produced no returns to current stockholders. Mednax's management efficiency ratios could be used to measure how well Mednax manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.07. In addition to that, Return On Capital Employed is expected to decline to 0. At present, Mednax's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 86.3 M, whereas Total Current Assets are forecasted to decline to about 382.4 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Marc Miller | Universal Health Services | 53 | |
| John Hollinsworth | Acadia Healthcare | 60 | |
| Steven Filton | Universal Health Services | 57 | |
| Marvin Pember | Universal Health Services | 66 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Christopher Heye | Prestige Brand Holdings | 53 | |
| Laurenc Harrod | Acadia Healthcare | 62 | |
| Jean Boyko | Prestige Brand Holdings | 60 | |
| Randall Goldberg | Acadia Healthcare | 41 | |
| Christopher Howard | Acadia Healthcare | 57 | |
| Debra Osteen | Universal Health Services | 62 | |
| Scott Romberger | Select Medical Holdings | 63 | |
| John Saich | Select Medical Holdings | 55 | |
| Thomas Mullin | Select Medical Holdings | 40 | |
| Robert Breighner | Select Medical Holdings | 55 | |
| Michael Tarvin | Select Medical Holdings | 63 | |
| Steve Filton | Universal Health Services | 66 | |
| Brent Turner | Acadia Healthcare | 52 | |
| Martin Jackson | Select Medical Holdings | 69 | |
| Paul Migaki | Prestige Brand Holdings | 60 | |
Management Performance
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0432 |
Mednax Inc Leadership Team
Elected by the shareholders, the Mednax's board of directors comprises two types of representatives: Mednax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mednax. The board's role is to monitor Mednax's management team and ensure that shareholders' interests are well served. Mednax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mednax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Clark, COO - Pediatrix Medical Group | ||
| Nikos Nikolopoulos, Executive Vice President Chief Strategy and Growth Officer | ||
| Michael Rucker, Independent Director | ||
| James MD, CEO Director | ||
| Pascal Goldschmidt, Independent Director | ||
| William Hawk, COO - American Anesthesiology | ||
| Mark Ordan, Chief Executive Officer, Director | ||
| C Richards, Chief Financial Officer, Executive Vice President, Principal Accounting Officer | ||
| John Pepia, Senior Vice President, Chief Accounting Officer | ||
| John Starcher, Independent Director | ||
| Shirley Weis, Independent Director | ||
| CPC MBA, Senior Services | ||
| Waldemar Carlo, Independent Director | ||
| Mike Ashford, President Market | ||
| Dana DreherRodwell, VP Officer | ||
| Joseph Calabro, Pres and COO | ||
| Guy Sansone, Independent Chairman of the Board | ||
| Debra Kaspar, President Market | ||
| Cheryl VanPatten, Senior Officer | ||
| Charles Lynch, Vice President - Strategy and Investor Relations, IR Contact Officer | ||
| Marc Richards, Executive CFO | ||
| Cheryl VanPattan, VP Officer | ||
| Curtis MD, Executive COO | ||
| Karl Wagner, President of American Anesthesiology | ||
| Charles CFA, Strategy Finance | ||
| Nanette Sanders, President Market | ||
| Enrique Sosa, Independent Director | ||
| Paul Gabos, Independent Director | ||
| Kevin Smith, Interim Vice President - Advanced Practice Anesthesia | ||
| Michael Stanley, President - Pediatrix Division | ||
| Roger Medel, Chief Executive Officer, Director | ||
| Donna Shalala, Independent Director | ||
| Cesar Alvarez, Independent Chairman of the Board | ||
| Dominic Andreano, Executive Vice President, General Counsel, Secretary | ||
| Mary Moore, Executive Vice President Chief Enterprise Risk and Legal Operations Officer | ||
| Carlos Migoya, Independent Director | ||
| Vivian LopezBlanco, CFO, Treasurer | ||
| Kevin Pitzer, President Market | ||
| Linda Chen, South President | ||
| Stephen Farber, Chief Financial Officer, Executive Vice President | ||
| Michael MD, President Market | ||
| Roger Hinson, President Pediatrix and Obstetrix Medical Group | ||
| Meghan Lublin, Chief VP | ||
| Manuel Kadre, Lead Independent Director | ||
| Michael Fernandez, Independent Director | ||
| Suzanne Heck, President Market | ||
| Lee Wood, Executive Operations | ||
| Roger MD, CoFounder Director | ||
| Karey Barker, Independent Director | ||
| Thomas McEachin, Independent Director | ||
| Daniel Corcoran, Senior Care |
Mednax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mednax a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0432 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 1.27 B | ||||
| Shares Outstanding | 84.03 M | ||||
| Shares Owned By Insiders | 1.37 % | ||||
| Shares Owned By Institutions | 98.63 % | ||||
| Number Of Shares Shorted | 4.12 M | ||||
| Price To Earning | 89.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Mednax Inc information on this page should be used as a complementary analysis to other Mednax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Mednax Stock analysis
When running Mednax's price analysis, check to measure Mednax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mednax is operating at the current time. Most of Mednax's value examination focuses on studying past and present price action to predict the probability of Mednax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mednax's price. Additionally, you may evaluate how the addition of Mednax to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Mednax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.31) | Revenue Per Share 24.265 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0432 | Return On Equity (0.07) |
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.